76 related articles for article (PubMed ID: 21334926)
1. Comments on the article "Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations" by Marfella et al.: (Journal of Diabetes and Its Complications 24 [2010] 79-83).
Avogaro A
J Diabetes Complications; 2011; 25(5):352-3. PubMed ID: 21334926
[No Abstract] [Full Text] [Related]
2. Reply to the "Comments on the article 'Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations'", by Avogaro (Journal of Diabetes and Its Complications 25 [2011] 352-353).
Marfella R; Paolisso G
J Diabetes Complications; 2011; 25(6):405-6. PubMed ID: 21775165
[No Abstract] [Full Text] [Related]
3. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations.
Marfella R; Barbieri M; Grella R; Rizzo MR; Nicoletti GF; Paolisso G
J Diabetes Complications; 2010; 24(2):79-83. PubMed ID: 19261490
[TBL] [Abstract][Full Text] [Related]
4. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
Sakamoto M; Nishimura R; Irako T; Tsujino D; Ando K; Utsunomiya K
Cardiovasc Diabetol; 2012 Aug; 11():92. PubMed ID: 22867630
[TBL] [Abstract][Full Text] [Related]
5. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.
Signorovitch JE; Wu EQ; Swallow E; Kantor E; Fan L; Gruenberger JB
Clin Drug Investig; 2011; 31(9):665-74. PubMed ID: 21819162
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial.
Göke R; Eschenbach P; Dütting ED
Diabetes Metab; 2015 Jun; 41(3):244-7. PubMed ID: 25457473
[TBL] [Abstract][Full Text] [Related]
8. Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose.
Nomoto H; Kimachi K; Miyoshi H; Kameda H; Cho KY; Nakamura A; Nagai S; Kondo T; Atsumi T
Endocr J; 2017 Apr; 64(4):417-424. PubMed ID: 28260702
[TBL] [Abstract][Full Text] [Related]
9. Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082.
Devries JH
Diabetes Care; 2013 Jan; 36(1):e12. PubMed ID: 23264295
[No Abstract] [Full Text] [Related]
10. Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082.
Makdissi A; Chaudhuri A; Kuhadiya N; Batra M; Dandona P
Diabetes Care; 2013 Jun; 36(6):e80. PubMed ID: 23704688
[No Abstract] [Full Text] [Related]
11. Response to Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082.
Rizzo MR; Barbieri M; Marfella R; Paolisso G
Diabetes Care; 2013 Jan; 36(1):e13. PubMed ID: 23264296
[No Abstract] [Full Text] [Related]
12. Beneficial Effects of Vildagliptin on Metabolic Parameters in Patients with Type 2 Diabetes.
Shimodaira M; Niwa T; Nakajima K; Kobayashi M
Endocr Metab Immune Disord Drug Targets; 2015; 15(3):223-8. PubMed ID: 25809193
[TBL] [Abstract][Full Text] [Related]
13. Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Gibbs JP; Fredrickson J; Barbee T; Correa I; Smith B; Lin SL; Gibbs MA
J Clin Pharmacol; 2012 Oct; 52(10):1494-505. PubMed ID: 22162539
[TBL] [Abstract][Full Text] [Related]
14. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
Pan C; Yang W; Barona JP; Wang Y; Niggli M; Mohideen P; Wang Y; Foley JE
Diabet Med; 2008 Apr; 25(4):435-41. PubMed ID: 18341596
[TBL] [Abstract][Full Text] [Related]
15. Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus.
Forst T; Dworak M; Berndt-Zipfel C; Löffler A; Klamp I; Mitry M; Pfützner A
Diabetes Obes Metab; 2013 Jun; 15(6):576-9. PubMed ID: 23384119
[TBL] [Abstract][Full Text] [Related]
16. Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes.
Prescrire Int; 2008 Oct; 17(97):188. PubMed ID: 19534040
[No Abstract] [Full Text] [Related]
17. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population.
Schweizer A; Dejager S; Foley JE; Couturier A; Ligueros-Saylan M; Kothny W
Diabetes Obes Metab; 2010 Jun; 12(6):485-94. PubMed ID: 20518804
[TBL] [Abstract][Full Text] [Related]
18. Reply to: Ahren B et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13(9): 775-783 and Ahren B et al. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011; 13(3): 193-203.
Carr RD; Katzeff HL; Alexander CM; Berger JP; Xu SS; Thornberry N
Diabetes Obes Metab; 2012 Apr; 14(4):383-4. PubMed ID: 22390829
[No Abstract] [Full Text] [Related]
19. Vildagliptin loaded triangular DNA nanospheres coated with eudragit for oral delivery and better glycemic control in type 2 diabetes mellitus.
Baig MMFA; Khan S; Naeem MA; Khan GJ; Ansari MT
Biomed Pharmacother; 2018 Jan; 97():1250-1258. PubMed ID: 29145151
[TBL] [Abstract][Full Text] [Related]
20. Oral agents for type 2 diabetes reduce HbA1c, are weight neutral.
Geriatrics; 2006 Sep; 61(9):2 p following 13. PubMed ID: 16998999
[No Abstract] [Full Text] [Related]
[Next] [New Search]
